CD44 and neoplasm: Mai et al., in their study, evaluated KRT and CD44 in a cohort of 302 NMIBC cases and found that a basal-like subgroup, identified by strong reactivity to KRT5 and CD44, constituted 12.9% of low-grade tumours and 17% of high-grade tumours.